[1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.10.3322/CA.2007.001018287387]Search in Google Scholar
[2. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008; 122:2286-93.10.1002/ijc.2339218224687]Search in Google Scholar
[3. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008; 266:99-115.10.1016/j.canlet.2008.02.05318381231]Search in Google Scholar
[4. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/ CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004; 22:307-328.10.1146/annurev.immunol.22.012703.10453315032580]Open DOISearch in Google Scholar
[5. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007; 13: 1083-8.10.1158/1078-0432.CCR-06-189317317815]Search in Google Scholar
[6. Schonbeck U, Libby P. The CD40/CD154 receptor/ ligand dyad. Cell Mol Life Sci. 2001; 58:4-43.10.1007/PL00000776]Search in Google Scholar
[7. Ochs HD, Hollenbaugh D, Aruffo A. The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency. Semin Immunol. 1994; 6:337-41.10.1006/smim.1994.10427532462]Open DOISearch in Google Scholar
[8. Qi CJ, Zheng L, Ma HB, Fei M, Qian KQ, Shen BR, Wu CP, Vihinen M, Zhang XG. A novel mutation in CD40 and its functional characterization. Hum Mutat. 2009; 30:985-94.10.1002/humu.2096719479954]Search in Google Scholar
[9. Murugaiyan G, Martin S, Saha B. CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol. 2007; 28:467-73.10.1016/j.it.2007.08.01017981086]Open DOISearch in Google Scholar
[10. Farahani M, Treweeke AT, Toh CH, Till KJ, Harris RJ, Cawley JC, Zuzel M, Chen H. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 2005; 19:524-30.10.1038/sj.leu.240363115674425]Search in Google Scholar
[11. Sabel MS, Yamada M, Kawaguchi Y, Chen FA, Takita H, Bankert RB. CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immunother 2000;49:101-108.10.1007/s00262005060810823420]Search in Google Scholar
[12. Li R, Chen WC, Wang WP, Tian WY, Zhang XG. CD40 signaling activated by agonistic anti-CD40 monoclonal antibody 5C11 has different effects on biological behavior of gastric carcinoma cells. Immunol Lett. 2010; 131:120-5.10.1016/j.imlet.2010.02.00720188757]Search in Google Scholar
[13. Kim SW, Lee HS, Yoon SK, Chung WC, Cho YS, Jeong JJ, et al. Expression of CD40 in gastric cancer and its effect on the apoptosis of gastric cancer cells. Korean J Gastroenterol. 2003; 42:274-82.]Search in Google Scholar
[14. Tomeczkowski J, Beilken A, Frick D, Wieland B, Konig A, Falk MH, et al. Absence of c-kit receptor and absent proliferative response to stem cell factor in childhood Burkitt’s lymphoma cells. Blood. 1995; 86:1469-80.10.1182/blood.V86.4.1469.bloodjournal8641469]Search in Google Scholar
[15. Matsuzawa A, Tseng PH, Vallabhapurapu S, Luo JL, Zhang W, Wang H, et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science. 2008; 321:663-8.10.1126/science.1157340266971918635759]Search in Google Scholar
[16. Fang J, Ding M, Yang L, Liu LZ, Jiang BH. PI3K/PTEN/ AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 2007; 19:2487-97.10.1016/j.cellsig.2007.07.025209400417826033]Open DOISearch in Google Scholar
[17. Deregibus MC, Buttiglieri S, Russo S, Bussolati B, Camussi G. CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem. 2003; 278:18008-14.10.1074/jbc.M30071120012637493]Search in Google Scholar
[18. Shafee N, Kaluz S, Ru N, Stanbridge EJ. PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett. 2009; 282:109-15.10.1016/j.canlet.2009.03.004270628519342157]Search in Google Scholar
[19. Edelmann J, Klein-Hitpass L, Carpinteiro A, Fuhrer A, Sellmann L, Stilgenbauer S, et al. Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk Res. 2008; 32:1565-72.10.1016/j.leukres.2008.03.00318407351]Search in Google Scholar
[20. Schnell CR, Stauffer F, Allegrini PR, O’Reilly T, McSheehy PM, Dartois C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 2008; 68:6598-607.10.1158/0008-5472.CAN-08-104418701483]Search in Google Scholar
[21. Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene. 2008; 27:3999-4007.10.1038/onc.2008.15261429018278068]Open DOISearch in Google Scholar
[22. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci USA. 2008; 105:9739-44.10.1073/pnas.0804123105245307018621722]Search in Google Scholar
[23. Dormond O, Contreras AG, Meijer E, Datta D, Flynn E, Pal S, et al. CD40-induced signaling in human endothelial cells results in mTORC2- and Aktdependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol. 2008; 181: 8088-95.10.4049/jimmunol.181.11.8088349598319018001]Search in Google Scholar
[24. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 2004; 103:3883-9.10.1182/blood-2003-05-163414726393]Search in Google Scholar